University of Hull   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Hull United Kingdom (1927)

Organization Overview

First Clinical Trial
2003
NCT00298662
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Castle Hill Hospital | Castle Hill Hospital, Hull | Daniel Carradice | Hull and East Yorkshire Hospitals NHS Trust | Hull and east Yorkshire NHS trust | Hull & East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom | Hull Royal Infirmary | Hull Royal Infirmary, Hull, United Kingdom. | Hull University | Hull York Medical School | Multiple Sclerosis Clinic - Hull Hospital | Queen's Centre for Haematology & Oncology, Castle Hill Hospital, Cottingham | Spire Hull and East Riding Hospital | United Kingdom: Hull University | University of Hull | University of Hull/Hull and East Yorkshire Hospitals NHS Trust | University of Hull, Hull York Medical School, Castle Hill Hospital | University of Hull, UK

Active Ingredients

Drugs in Phase 4 Trials (21)

atorvastatin (lipitor) (1 trial)

budesonide (rhinocort) (1 trial)

chlorhexidine (hibitane) (1 trial)

clavulanate (Augmentin) (1 trial)

clindamycin (cleocin) (1 trial)

epinephrine (levophed) (1 trial)

erdosteine (1 trial)

fluticasone (cutivate) (1 trial)

formoterol (foradil) (2 trials)

iodine (1 trial)

laropiprant (1 trial)

lidocaine (xylocaine) (1 trial)

metronidazole (flagyl) (1 trial)

montelukast (singulair) (1 trial)

prednisone (meticorten) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

ramipril (altace) (1 trial)

salmeterol (serevent) (1 trial)

sodium bicarbonate (1 trial)

sodium tetradecyl sulfate (Sotradecol) (2 trials)

teicoplanin (1 trial)

Drugs in Phase 3 Trials (22)

apixaban (eliquis) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

capecitabine (xeloda) (1 trial)

dabigatran (pradaxa) (1 trial)

edoxaban (savaysa) (1 trial)

empagliflozin (jardiance) (1 trial)

escitalopram (lexapro) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

metformin (glucophage) (1 trial)

omeprazole (prilosec) (1 trial)

ranitidine (zantac) (1 trial)

rivaroxaban (xarelto) (1 trial)

semaglutide (Ozempic) (1 trial)

sitagliptin (januvia) (2 trials)

streptococcus salivarius (1 trial)

theobromine (1 trial)

vsl #3 (1 trial)

Drugs in Phase 2 Trials (13)

acetylsalicylic acid (aspirin) (1 trial)

ambroxol (1 trial)

azithromycin (zithromax) (1 trial)

beclomethasone (vanceril) (1 trial)

dalteparin (fragmin) (1 trial)

gefapixant (1 trial)

gemcitabine (gemzar) (1 trial)

iab22m2c (1 trial)

interferon beta-1b (betaseron) (1 trial)

juvista (1 trial)

oxygen (2 trials)

tacrolimus (prograf) (1 trial)

tetrahydrocannabinol (1 trial)

Drugs in Other Trials (14)

aspartame (1 trial)

citric acid (1 trial)

cocoa bean (2 trials)

dapagliflozin (farxiga) (1 trial)

gliclazide (1 trial)

insulin human (humulin) (3 trials)

insulin lispro (humalog) (1 trial)

isoflavone (1 trial)

l-epigallocatechin (1 trial)

liraglutide (victoza) (1 trial)

pioglitazone (actos) (1 trial)

soybean (1 trial)

sucrose (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Aneurysm (Phase 4)

Anxiety Disorders (Phase 3)

Aortic Aneurysm (Phase 4)

Aortic Aneurysm, Abdominal (Phase 4)

Atrial Fibrillation (Phase 3)

Bronchial Hyperreactivity (Phase 3)

Cerebral Hemorrhage (Phase 3)

Cicatrix (Phase 2)

Communicable Diseases (Phase 4)

Cough (Phase 4)

Diarrhea (Phase 3)

Fibrosis (Phase 2)

Glioblastoma (Phase 2)

Heart Failure (Phase 2)

Hemorrhage (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 2)

Infections (Phase 4)

Leg Ulcer (Phase 2)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Multiple Sclerosis (Phase 2)

Myocardial Reperfusion Injury (Phase 2)

Pancreatic Neoplasms (Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Fibrosis (Phase 2)

Rectal Neoplasms (Phase 3)

Reperfusion Injury (Phase 2)

Sarcoidosis (Phase 2)

Sarcoidosis, Pulmonary (Phase 2)

Sclerosis (Phase 2)

Surgical Wound Infection (Phase 4)

Syndrome (Phase 4)

Thromboembolism (Phase 2)

Tissue Adhesions (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Varicose Veins (Phase 4)

Venous Insufficiency (Phase 4)

Wound Infection (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 70